Evaluation of the efficacy and safety of an acrylic phakic intraocular lens in cases of high myopia

Purpose The purpose of the study is to measure the safety and efficacy of Eyecryl PC pIOL in treating high myopia. Patients and methods Data were retrieved from the electronic health records of patients who received Eyecryl PC pIOL implants to treat high myopia between January 2020 and January 2022, and a retrospective analysis was conducted. Results This investigation comprised 41 eyes from 21 patients. The patients’ ages were between 20 and 52 years. There was vision improvement at the end of the follow-up appointments, with a significant decline in the postoperative spherical equivalent and refraction. At 12 months, the safety index, calculated as the ratio of postoperative corrected distance visual acuity (CDVA) to preoperative CDVA, was 1.78. Meanwhile, the efficacy index, which represents the ratio of postoperative uncorrected distance visual acuity to preoperative CDVA, was 1.25. Four (9.8%) cases had postoperative high intraocular pressureand were controlled on topical antiglaucoma treatment. No serious, vision-threatening intraoperative or postoperative complications were encountered. No cases of endothelial decompensation, visually significant cataracts, or intraventricular opacities developed within the first year of follow-up. Conclusion The use of the Eyecryl pICL offers an economical alternative to high myopia patients who are not suitable candidates for laser refractive surgery. In our 12-month follow-up, we found significant improvements in both UCDVA and CDVA, with very few associated complications.